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Congenital nephrotic syndrome (NPHS1): Features resulting clinical entity among nephrotic syndromes [1]. It is an
from different mutations in Finnish patients. autosomal recessive disorder with an incidence of 1:8200
Background. Congenital nephrotic syndrome (NPHS1) is a
births in Finland [2, 3]; in other countries the incidencerare disease inherited as an autosomally recessive trait. The
is clearly lower [4], so that approximately one half of theNPHS1 gene mutated in NPHS1 children has recently been
identified. The gene codes for nephrin, a cell-surface protein reported NPHS1 patients have been diagnosed in Finland.
of podocytes. Two mutations, named Fin-major and Fin-minor, The classic findings in NPHS1 include prematurity, largehave been found in over 90% of the Finnish patients. In this
placenta, and proteinuria, which already begins in uterostudy, we correlated the NPHS1 gene mutations to the clinical
features and renal findings in 46 Finnish NPHS1 children. [5]. Nephrotic syndrome with heavy proteinuria, hypo-
Methods. Clinical data were collected from patient files, and proteinemia, edema, and secondary manifestations is usu-
kidney histology and electron microscopy samples were re- ally detected shortly after birth. Currently, children withevaluated. The expression of nephrin was studied using immu-
NPHS1 are successfully treated with active protein andnohistochemistry, Western blotting, and in situ hybridization.
Results. Nephrotic syndrome was detected in most patients nutritional support, followed by bilateral nephrectomy
within days after birth regardless of the genotype detected. No and dialysis, and finally, by renal transplantation [6].
difference could be found in neonatal, renal, cardiac, or neuro-
The gene for NPHS1 (NPHS1 gene) has been localizedlogical features in patients with different mutations. Nephrin
to chromosome 19q13.1 [7, 8] and was recently identifiedwas not expressed in kidneys with Fin-major or Fin-minor mu-
tations, while another slit diaphragm-associated protein, ZO-1, as a novel 29-exon gene [9]. The protein product of this
stained normally. In electron microscopy, podocyte fusion and gene was termed nephrin. It is a transmembrane protein
podocyte filtration slits of various sizes were detected. The
of the immunoglobulin superfamily containing 1241 aminoslit diaphragms, however, were missing. In contrast to this, a
acids. Nephrin is produced by glomerular podocytes, andnephrotic infant with Fin-major/R743C genotype expressed
nephrin in kidney had normal slit diaphragms and responded recently, we localized nephrin at the slit diaphragm of
to therapy with an angiotensin-converting enzyme inhibitor the glomerular podocytes, suggesting that this structureand indomethacin.
and nephrin play an essential role in the normal glomeru-Conclusions. The most common NPHS1 gene mutations,
Fin-major and Fin-minor, both lead to an absence of nephrin lar filtration process [10].
and podocyte slit diaphragms, as well as a clinically severe form The two most common mutations in the NPHS1 gene
of NPHS1, the Finnish type of congenital nephrotic syndrome.
have been named Fin-major and Fin-minor and are
highly enriched in the Finnish population [9]. Sixty-five
percent of the Finnish patients were homozygous for theCongenital nephrotic syndromes (CNS) form a heter-
Fin-major mutation, and 8% were homozygous for Fin-ogenous group of diseases characterized by proteinuria
minor. Sixteen percent of the patients were compoundshortly after birth [1]. NPHS1 (MIM 256300) is a distinct
heterozygous. Eight percent of the patients were Fin-
major heterozygotes with missense mutations in the otherKey words: nephrin, slit diaphragm, autosomal recessive inheritance,
proteinuria in utero, hypoproteinemia. chromosome, and one patient had three missense muta-
tions. The Fin-major mutation results in a frameshift andReceived for publication January 7, 2000
a stop codon in exon 2 and a truncated protein of only 90and in revised form March 30, 2000
Accepted for publication April 7, 2000 amino acids. Fin-minor mutation is a nonsense mutation
in exon 26 and leads to a truncated 1109-residue protein.Ó 2000 by the International Society of Nephrology
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In non-Finnish patients, a great variety of mutations have
been described recently, including insertions, deletions,
and nonsense and missense mutations [11]. These muta-
tions were scattered along the entire NPHS1 gene.
The clinical features of NPHS1 children were thor-
oughly studied in the early 1970s [5]. Since then, the
diagnostic methods and the management of these chil-
dren have changed dramatically. This and the discovery
of the genetic basis of this disease prompted us to per-
form a systematic analysis of the clinical manifestations
and renal pathology of the Finnish NPHS1 patients. This
seemed especially interesting since the two most com-
mon mutations, Fin-major and Fin-minor, affect the op-
posite ends of the nephrin molecule.
METHODS
Genetic analysis
The identification of the NPHS1 gene and an analysis
of the mutations of NPHS1 children have been described
[9]. The total of 46 patients studied included 29 patients
homozygous for the Fin-major mutation, 4 patients ho-
mozygous for the Fin-minor mutation, and 8 compound
heterozygotes for these mutations. Three patients had a
Fin-major mutation in one and an identified missense
mutation in the other gene. One patient had a Fin-major
mutation in one gene and probably a splice mutation in
the other gene. Finally, one patient had three missense
mutations (Fig. 1).
Patient management
Fig. 1. NPHS1 gene and mutations in Finnish patients. (A) NPHS1The treatment of children with NPHS1 occurred in
gene. Fin-major mutation is a 2 bp deletion in exon 2, and Fin-minorthree stages, as has been described earlier [1]. Briefly, mutation is a nonsense mutation in exon 26. The three missense muta-
after nephrosis was diagnosed, the patients were supple- tions are also indicated. (B) Nephrin molecule. Fin-major mutation
leads to a truncated protein of 90 amino acids and Fin-minor to amented with daily albumin infusions and a high-calorie
truncated protein of 1109 amino acids. W64S is a change of tryptophandiet. The medication included thyroxin, sodium warfarin, to serine in Ig-1. C465T is a change of cysteine to tyrosine in Ig-5, and
and prompt antibiotic therapy for septic infections. Bi- R743C is a change of arginine to cysteine in Ig-7. (C) Genotypes of
the Finnish NPHS1 patients included in this study.lateral nephrectomy was performed when the children
weighed about 7 kg and peritoneal dialysis was started.
Renal transplantation either from a parent or from a
cadaver donor was done when the patient weighed at
Light and electron microscopy of kidney samples
least 9 kg [12].
Histologic slides of the nephrectomized kidneys be-
Collection of clinical data tween the years 1986 and 1998 were collected and re-
examined. Forty-four cases were obtained. The ages ofThe clinical symptoms and signs as well as laboratory
the patients at nephrectomy ranged from 4 months tovalues during the nephrotic stage were analyzed retro-
3.7 years, most of the nephrectomies (36 out of 44) beingspectively. These included birth weight and height, pla-
performed between 6 and 18 months. Abnormalities ofcental weight, gestational age, the time of recognition of
glomeruli, tubuli, and blood vessels and interstitial fi-the disease, blood, and urine biochemistry. The amount
brosis and inflammation were recorded. The number ofof protein loss was evaluated by recording urine protein
obsolescent glomeruli, extension of tubular microcysts,measurements and the albumin substitution required at
interstitial fibrosis, and inflammation were arbitrarilythe age of three to six months. Neurological status, find-
graded from nil to 31. The histology score was obtainedings on electroencephalography (EEG), and computed
by adding these together (Table 2).tomography (CT) of the brain were recorded. The results
of cardiac examinations were analyzed. Electron microscopy was performed according to stan-
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Table 1. Neonatal and nonrenal characteristics in NPHS1 children with different mutationsa
Mutation
Major/major Major/minor Minor/minor Othersb
Finding N 5 29 N 5 8 N 5 4 N 5 5
Neonatal
Gestational age weeks 36.3 (32.7–39.4) 36.4 (35.0–37.7) 35.1 (32.0–37.0) 37.9 (36.0–39.4)
Birth weight g 2615 (1620–3410) 2540 (2010–3040) 2010 (1450–2270) 2657 (1840–3480)
Birth height cm 47 (43–52) 48 (46–49) 45 (43–46) 48 (45–50)
ISP % 38.6 (21.3–56) 38.0 (30–46) 47.5 (39.6–59) 40.5 (37–58)
Neurological
Hypotonia 26/28c 5/7c 4/4c 4/5c
EEG abnormalities 10/26 2/7 1/4 0/4
CT/MRI abnormalities 12/26 4/7 1/4 1/4
Cardiac findingsd 6/26 2/7 1/4 3/5
a Results are given as means and range
b These included three patients with Fin-major in one gene and missense mutation in the other gene, one patient with three missense mutations, and one patient
with Fin-major mutation in one gene and a probable splice mutation in the other gene (Fig. 1)
c Number of patients with the finding/total number of patients with adequate data
d Cardiac findings include mild pulmonary stenosis (5 patients), cardiac hypertrophy (3 patients) and atrial septal defect (1 patient)
dard procedures. Samples from nephrectomized kidneys other against the intracellullar part of the nephrin mole-
cule (Ruotsalainen et al, manuscript in preparation). Anti-were immediately fixed in 2.5% glutaraldehyde and then
washed in phosphate buffer. After dehydration with al- serum against ZO-1 came from Zymed Laboratories Inc.
(San Francisco, CA, USA).cohol, the samples were embedded in epoxy resin for thin
sectioning and electron microscopy. The samples came Western blotting for nephrin was performed on glomer-
ular extracts obtained from four nephrectomized kidneys.from two patients homozygous for the Fin-major muta-
tion, two patients who were compound heterozygous for Glomerular sieving was performed as previously described
[14]. The samples came from two patients homozygousthe Fin-major and Fin-minor mutations, and one patient
with Fin-major mutation in one chromosome and a mis- for the Fin-major mutation and two patients with com-
pound heterozygotes for Fin-major and Fin-minor muta-sense mutation R743C in the other chromosome (Fig. 1).
tions. Ten micrograms of Triton X-100–soluble protein
Expression of nephrin in NPHS1 kidneys were separated on 4 to 20% gradient gel and transferred
into polyvinyl difluoride membrane. Membrane was blot-In situ hybridization for nephrin mRNA was performed
ted with monoclonal antibody reacting against the extra-as previously described [13]. Briefly, tissue sections were
cellular part of nephrin (Ruotsalainen et al, manuscriptincubated with 1.2 3 106 33P-labeled (1000 Ci/mmol; Am-
in preparation), and mouse IgG was detected with alkalineersham, Arlington Heights, IL, USA) antisense and sense
phosphatase-conjugated anti-mouse IgG (Dako Corpora-riboprobes in a total volume of 80 mL. The probes were
tion, Carpinteria, CA, USA) and 5-bromo-4-chloro-3-synthesized by subcloning a cDNA fragment of 287 bp
indoyl phosphate p-toluidine salt and p-nitro blue tera-corresponding to exon 10 in human NPHS1 gene into
zolium chloride.pBluescript and antisense and sense RNAs produced us-
ing T3 and T7 RNA polymerases, respectively. Parafor-
Statisticsmaldehyde-fixed cryosections came from two patients
homozygous for the Fin-major mutation, two patients ho- Statistical analyses were carried out using the Student’s
t-test.mozygous for the Fin-minor mutation, and two patients
who were compound heterozygous for these mutations.
Immunofluorescence studies of nephrin in nephrecto-
RESULTSmized kidneys and in one kidney biopsy were performed
Neonatal and nonrenal featuresin a standard fashion. Paraformaldehyde-fixed cryosections
were used. The tissue samples came from four patients The majority (38 out of 46, 83%) of NPHS1 children
homozygous for Fin-major mutation, one patient homo- were born prematurely (,38th week) with a birth weight
zygous for Fin-minor mutation, and three patients who ranging from 1450 to 3480 g. Only two newborns were
were compound heterozygous for these. One sample came small for their gestational age. Amniotic fluid was often
meconium stained, but a great majority of the neonatesfrom a child with Fin-major mutation in one chromosome
and R743C missense mutation in the other (Fig. 5). Two did not have pulmonary problems. The index of placental
weight/birth weight (ISP) was over 25% in all exceptpolyclonal rabbit anti-nephrin antisera were available.
One was directed against the extracellular [10] and the one newborn with Fin-major/Fin-major mutations. No
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Table 2. Renal findings in NPHS1 patients at the nephrotic stage
Nephrosis diagnosed Proteinuria Hematuria Albumin substitution
Patient genotype at the first week .10 g/L .100/field g/kg/day Histologic scorea
Major/major 19/26b 12/15b 15/16b 4.1 (2.8–6.3)c (N516) 5.0 (0–10) (N524)
Major/minor 8/8 3/5 5/5 3.7 (0.9–4.9) (N56) 6.9 (3–12) (N57)
Minor/minor 4/4 3/4 4/4 3.4 (1.6–4.1) (N54) 5.8 (1–10) (N54)
Othersd 3/4 4/5 1/1 3.7 (3.0–4.5) (N53) 5.5 (1–12) (N54)
a The number of obsolescent glomeruli, extension of tubular microcysts, interstitial fibrosis and inflammation were graded from nil to 3 and added into a histologic
score (maximum score 12) (Methods section)
b Number of patients with the finding/total number of patients with adequate data
c Results are given as means and range
d The same as in Table 1
Fig. 2. In situ hybridization for nephrin mRNA in normal and NPHS1 kidneys. A quite normal signal is seen in kidney glomeruli from patients
with Fin-major and Fin-minor mutations.
major differences were observed in the neonatal findings patients with different mutations. In 82% of the infants,
nephrotic syndrome was diagnosed within the first weekbetween the different genotypes (Table 1).
Infants with NPHS1 did not have any major nonrenal after birth (Table 2). The diagnosis was delayed from
two weeks to two months in seven infants homozygousmalformations. On the other hand, minor functional dis-
orders in central nervous system and heart were quite for the Fin-major mutation (including two pairs of twins).
No difference in the rate of hematuria between patientscommon during the nephrotic stage. Most of the children
had muscular hypotonia regardless of the mutation (Ta- with different mutations could be found. Also, no differ-
ence in the amount of intravenous albumin substitutionble 1). EEG was performed to 41 infants at the age of
needed to maintain serum albumin over 15 g/L was de-6 to 12 months. The finding was normal in 28 (68%) cases.
tected. All patients had normal creatinine values duringMild or moderate background activity was recorded in
the first months. Five patients with Fin-major and Fin-nine patients and focal activity in four patients (Table 1).
minor mutations received angiotensin-converting enzymeEither CT or magnetic resonance imaging (MRI) or both
(ACE) inhibitor therapy without a need for a reductionwere performed on 41 patients at the age of 6 to 12
of proteinuria or albumin substitution.months. Over one third (12 out of 26) of patients homo-
The kidneys were nephrectomized when the infantszygous for Fin-major mutation, four out of seven com-
weighed over 7 kg. In histopathological examination,pound heterozygotes, and one Fin-minor homozygote
glomeruli showed mesangial hypercellularity, hyperlo-had mild atrophic changes.
bulated capillary tufts, and some scarring. Also, micro-During the nephrotic stage, many children had mild car-
cystic dilation of both proximal and distal tubuli as well asdiac hypertrophy, as shown by x-ray films. Cardiac evalu-
interstitial fibrosis and inflammation could be observedation, including ultrasound examination, was performed
(Table 2). No major differences were found betweenin 42 patients during the nephrotic stage. Minor disor-
different genotypes.ders, including cardiac hypertrophy, mild pulmonary ste-
nosis, and atrial septal defect, were observed, but there
Nephrin and the slit diaphragm in NPHS1 kidneyswas no accumulation of any of these defects in any pa-
In situ hybridization for nephrin mRNA showed quitetient groups (Table 1).
normal signal in nephrectomized NPHS1 kidneys with
Renal findings Fin-major or Fin-minor mutations (Fig. 2). However,
immunofluorescence staining with antibodies reactingProteinuria and low serum albumin levels were usually
already found in the first samples taken after birth in against the intracellular and extracellular part of nephrin
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Fig. 3. Immunofluorescence staining for nephrin and ZO-1 in normal and NPHS1 kidneys. No staining of nephrin is seen in NPHS1 glomeruli
with different genotypes using polyclonal antibodies against the extracellular part (a-e-nephrin) or intracellular part (a-i-nephrin) of nephrin. The
staining pattern of ZO-1 (a-ZO-1) is similar to that of normal kidney in all genotypes.
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expression of nephrin, and slit diaphragms were evident
in electron microscopy (Fig. 6B, C). After taking a kidney
biopsy, therapy with prednisone and cyclophosphamide
was also tried, but they had no effect on the residual
proteinuria. The child is now 2.5 years old with only mild
proteinuria (,1 g/L).
DISCUSSION
This study shows that the two most common mutations
Fig. 4. Western immunoblotting for nephrin in glomerular extracts of the NPHS1 gene, Fin-major and Fin-minor, both lead
from normal and NPHS1 kidneys. No expression of nephrin is seen in to the severe form of congenital nephrosis. The clinical
glomeruli with Fin-major and Fin-minor mutations, as detected by a
features include prematurity, large placenta, heavy pro-monoclonal antibody against the extracellular part of nephrin.
teinuria, and full-blown nephrosis soon after birth. Also,
these patients do not react to ACE inhibitors or indo-
methacin.
remained negative in kidneys with Fin-major and Fin- As the Fin-major mutation results in a nephrin mole-
minor mutations (Fig. 3). The expression of another slit cule of only 90 amino acid residues [9], it seemed proba-
diaphragm protein, ZO-1, was normal (Fig. 3). In West- ble that Fin-major homozygotes would not show immu-
ern blot analysis, a monoclonal anti-nephrin antibody noreactivity to nephrin. Indeed, the Fin-major mutation
showed no immunoreactive bands in Triton-X extracts leads to a complete absence of the protein. In contrast,
of isolated glomeruli from NPHS1 kidneys with Fin- Fin-minor mutation only leads to the loss of a part (132
major and Fin-minor mutations (Fig. 4). terminal amino acids) of the intracellular domain of
Electron microscopy of the glomeruli showed podo- nephrin [9]. Therefore, the protein, although multifunc-
cyte fusions, as reported previously [15]. Irregular podo- tional, could be expected to be expressed and present
cyte foot processes were also seen in kidneys with Fin- on the podocyte plasma membrane. This was, however,
major and Fin-minor mutations (Fig. 5). Filtration slits not the case, as we saw no immunoreactivity of nephrin
between the foot processes were of different sizes. In in immunofluorescence staining of the kidney sections or
about a quarter, the slits were extremely narrow (,20 immunoblotting of glomerular extracts. The finding that
nm), and on the other hand, slits with a width of up to the Fin-minor mutation leads to an absence of nephrin
90 nm were occasionally observed. More importantly, on the podocyte surface was unexpected.
no filamentous image of slit diaphragm was seen in any Nephrin has been localized to the slit diaphragm re-
of the 76 filtration slits analyzed in NPHS1 glomeruli with gion of glomeruli [10]. Therefore, it was of interest to
Fin-major and Fin-minor mutations (Fig. 5). In normal see how the lack of nephrin in kidneys with Fin-major
kidneys, the image of slit diaphragm was seen in 52 of and Fin-minor mutations affects the ultrastructure of the
the 82 podocytes slit areas (64%) studied. The width of glomerular filtration barrier. As reported previously [15],
the filtration slit also showed less variation in normal an irregular pattern and fusion of podocyte foot pro-
glomeruli and was between 25 and 50 nm in all slit pores cesses was seen in electron microscopy. In addition, quite
studied. normal-looking podocyte slits were observed. However,
no slit diaphragms were present in these slits. This sup-
Findings in patients with missense mutations ports the idea that nephrin is an important component of
Figure 1 lists the five patients with missense mutations slit diaphragm and plays a crucial role for the glomerular
in at least one gene. Four of these were clinically indistin- filtration barrier.
guishable from children with Fin-major and/or Fin-minor The width of the slit pore in NPHS1 glomeruli showed
mutations in both genes. Unfortunately, all of these four greater variation than in normal kidneys. Narrow slits
were born in the early 1990s, and no renal tissue was (,20 nm) were present in NPHS1 kidneys but not in
available for analysis of nephrin expression. normal glomeruli. Since the structure of the slit dia-
An interesting exception to these findings was a child phragm is still largely unknown, the molecular basis for
with Fin-major/R743C mutations (Fig. 6). She was born this phenomenon remains to be seen. The zonula oc-
in 1997, and nephrosis was detected immediately after cludens-1-antigen (ZO-1) is a cytosolic component of
birth. Proteinuria ranged from 2.8 up to 75 g/L, and ACE the slit diaphragm region in human kidney [16], and
inhibitor and indomethacin therapy was started at the recently, P-cadherin was localized to the this area [17].
age of three months. After two months of therapy, pro- The podocyte surface is also rich of negatively charged
teinuria decreased to a level of 1 to 3 g/L (Fig. 6A). Renal glycoproteins, which have an impact on the foot process
interactions. The role of these components in the ultra-biopsy was performed. The kidney glomeruli showed
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Fig. 5. Electron microscopy of NPHS1 and control kidneys. (A) The capillary wall in Fin-major homozygote showing podocyte foot processes
(arrows) of various size. (B) Filtration slits of various size in the NPHS1 kidney of a Fin-major/Fin-minor genotype. No slit diaphragms are seen.
(C ) A narrow filtration slit in a NPHS1 kidney of Fin-major homozygote. (D and E ) Podocyte filtration slits in normal human kidney. The slit
diaphragms are seen as filamentous images (arrows).
structural organization of the podocyte slit in normal tional areas. They did not correlate these staining patterns
to the NPHS1 genotype, and the significance of theirand NPHS1 glomerulus is unclear.
Interestingly, the expression of ZO-1 was normal in findings remains unclear. In our study, the negative im-
munofluorescence staining and immunoblotting of theNPHS1 kidneys, indicating that the lack of nephrin does
affect the expression of ZO-1. This is different from glomerular extracts as well as the lack of slit diaphragm
in kidneys with Fin-major and Fin-minor mutationsthat seen in rats. Injection of antibodies against a slit
diaphragm antigen, p51, induces nephrosis in rats and strongly indicate that both mutations lead to the total
lack of functional nephrin in these patients.leads to progressive decline in stainable ZO-1 [18]. It
was recently shown that p51 antigen is an epitope of Based on the immunohistologic and microscopic find-
ings, it is not surprising that the clinical features of chil-nephrin molecule [19], suggesting that nephrin and ZO-1
in this model are linked together. dren with Fin-major and Fin-minor mutations were simi-
lar. Both mutations lead to full-blown nephrosis soonRecently, Holtho¨fer et al described the expression of
nephrin in normal and NPHS1 kidneys using two poly- after the birth, and large amounts of albumin were
needed to substitute the protein loss. Also, therapy withclonal antibodies against nephrin [20]. In immunofluo-
rescence nephrin was not detected in NPHS1 kidneys, agents reducing the glomerular filtration pressure were
not successful in diminishing the proteinuria. Previously,but in immunoelectron microscopy, they noticed some
nephrin-specific gold particles at the flattened apical sur- non-Finnish CNS patients responding to ACE inhibitors
and indomethacin have been published [21, 22].face of podocytes and rarely at the intercellular junc-
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Fig. 6. Urinary protein excretion and renal findings in NPHS1 patient with Fin-major/R743C mutations. (A) Effect of antiproteinuric therapy on
urinary protein excretion. Enalapril and indomethacin were started at the age of three months. The dosing was gradually increased, and two
months later (indomethacin 2.2 mg/kg/day and enalapril 1.3 mg/kg/day), a reduction in urinary protein from about 30 g/L to 1 to 3 g/L was observed.
After this, prednisone and cyclophosphamide were given for four months and six weeks, respectively, to decrease further the protein excretion.
No clear response was observed with either of the drugs. (B) Kidney biopsy was taken at the age of five months (after the decrease of proteinuria),
and in immunofluorescence staining, nephrin was expressed normally in the glomeruli. (C) In electron microscopy, fusion of foot processes as well
as quite normal-looking foot processes could be seen. Filamentous images of slit diaphragms looked normal between the foot processes (arrows).
Our patient material, however, included one impor- (so-called Finnish type) or to a less severe clinical picture
of CNS. Based on the present data, a renal biopsy ontant exception: a child with a Fin-major mutation in one
gene and a missense mutation (a change of arginine-743 infants with congenital nephrosis who are not Fin-major
or Fin-minor homozygotes or compound heterozygotesto cysteine in the extracellular Ig-5 domain) in the other
one. Her nephrosis was detected immediately after birth, may be indicated. If the kidneys express nephrin and
electron microscopy reveals the presence of slit dia-and proteinuria up to 75 g/L was measured during the
first months. However, she responded to enalapril and phragms, a response to an ACE inhibitor and indometha-
cin might be expected. On the other hand, if immunoflu-indomethacin therapy and has avoided renal transplanta-
tion. The obvious explanation came from the micro- orescence staining for nephrin is negative, the chances
for a response are small, and renal transplantation seemsscopic studies. Her kidneys expressed nephrin, and slit
diaphragms were present between the podocyte foot pro- to be the only option.
The expression of nephrin in nonrenal tissues is notcesses. Thus, although the missense mutation in the
NPHS1 gene led to a “functional” disorder in her glo- completely known. Northern hybridization did not re-
veal nephrin-RNA in fetal placenta, liver, brain, lung,merular filtration barrier, the pharmacological reduction
of the glomerular filtration pressure was enough to re- muscle, or pancreas [9]. Recent findings, however, have
shown that mRNA for nephrin is present in cells of theduce the protein leakage dramatically.
Recently, over 30 mutations have been detected in neural tube in developing mouse embryos (Putaala et
al, manuscript submitted for publication). Clinically, chil-non-Finnish patients with CNS [11]. It is clear that these
mutations may lead to the severe, therapy-resistant form dren with NPHS1 do not have major defects in other
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